Evaluating DNA impurities in recombinant adeno-associated virus

A new study in the peer-reviewed journal Human Gene Therapy indicates that DNA impurities derived from plasmid and host cell DNA are encapsulated into recombinant adeno-associated virus (rAAV) capsids as single-stranded DNA. Click here to read the article now.

rAAVs are widely used viral vectors in human gene therapy, but contamination from DNA impurities, such as plasmid and host cell DNA, remains a significant quality control concern for their manufacture. In this study, Kazuhisa Uchida, from Kobe University, and coauthors examined several purifies rAAV samples and found that they contained DNA derived from three plasmids. They determined that the impurities were encapsulated into the rAAV capsids as single-stranded DNA.

The investigators suggest that when rAAVs are used in gene therapy, the adverse effects of the single-stranded form of DNA impurities may differ from those of double-stranded DNA. “It may be necessary to reconsider or evaluate the effects of single-strand form of DNA impurities independently,” stated the investigators.

“Studies like this are incredibly important to better understand how DNA impurities are generated and what sources they come from during the production process in order to improve the efficiency of manufacturing and purity of the final rAAV product, which will help make the therapy more effective and reduce adverse events for patients,” says Managing Editor of Human Gene Therapy Thomas Gallagher, PhD, from the University of Massachusetts Chan Medical School.

About the Journal
Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy and eight other international gene therapy societies, was the first peer-reviewed journal in the field and provides all-inclusive access to the critical pillars of human gene therapy: research, methods, and clinical applications. The Journal is led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, and an esteemed international editorial board. Human Gene Therapy is available in print and online. Complete tables of contents and a sample issue are available on the Human Gene Therapy website.

About Mary Ann Liebert, Inc., a Sage Company
Mary Ann Liebert, Inc. is a global media company dedicated to publishing and delivering impactful peer-reviewed research in biotechnology & life sciences, specialized clinical medicine, public health and policy, and technology & engineering. Since its founding in 1980, the company has focused on providing critical insights and content that empower researchers and clinicians worldwide to drive innovation and discovery.